Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Zimmer Biomet (NYSE:ZBH) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06, FiscalAI reports. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 EPS. Zimmer Biomet updated its FY 2026 guidance to 8.470-8.590 EPS.

Here are the key takeaways from Zimmer Biomet’s conference call:

• Positive Sentiment: Zimmer Biomet reported Q2 net sales of $2.177 billion, up 4.0% organically at constant currency, exceeding expectations; U.S. organic growth was 4.6%, led by hips, technology, and higher-growth S.E.T. businesses.
• Positive Sentiment: The company raised its 2026 organic revenue growth outlook to 2.25%-3.25% from 1%-3% and adjusted EPS guidance to $8.47-$8.59; reported sales growth guidance increased to 3.9%-4.9%.
• Positive Sentiment: New products and technology are gaining traction, including the Z1 hip stem, HAMMR, OrthoGrid, iodine-coated hips in Japan, and ROSA Shoulder; technology sales grew 21.5% overall and more than 50% in the U.S.
• Neutral Sentiment: The U.S. sales-force transformation is progressing ahead of expectations, but Zimmer Biomet plans to continue investing in specialized commercial capabilities through 2027, putting pressure on margins; Q2 adjusted operating margin declined 210 basis points to 25.7%.
• Positive Sentiment: Operating cash flow rose 18% to $448 million and free cash flow increased 24% to $308 million; the company plans to repurchase up to $1 billion of shares in 2026, including $500 million already repurchased in the first half.

Zimmer Biomet Price Performance

ZBH stock traded up $2.40 during midday trading on Wednesday, reaching $98.21. 2,758,828 shares of the stock were exchanged, compared to its average volume of 2,315,474. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $108.29. The company has a fifty day moving average price of $89.30 and a 200 day moving average price of $89.95. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The stock has a market capitalization of $19.00 billion, a PE ratio of 25.49, a P/E/G ratio of 2.86 and a beta of 0.45.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q2 results exceeded expectations. Zimmer Biomet reported $2.177 billion in second-quarter sales, up 4.8% year over year and above the $2.13 billion analyst estimate. Adjusted diluted EPS was $2.07, beating consensus of $2.01. Zimmer Biomet Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year guidance was raised. The company now expects 2026 adjusted EPS of $8.47 to $8.59, broadly in line with the $8.48 consensus, and revenue of approximately $8.6 billion, above the roughly $8.5 billion analyst estimate. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: Underlying growth remained healthy. Second-quarter sales increased 4.0% on an organic constant-currency basis, while reported diluted EPS rose 33.8% to $1.03, supporting the market’s favorable initial reaction. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted profitability was mixed. Adjusted EPS of $2.07 was unchanged from the prior-year period despite revenue growth, indicating that operating-cost or margin pressures offset some of the sales improvement. Analysts and investors will likely focus on the company’s margin trajectory and execution against the upgraded outlook.

Analyst Upgrades and Downgrades

Several research analysts have commented on ZBH shares. Stifel Nicolaus lowered their price objective on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Robert W. Baird set a $92.00 price target on Zimmer Biomet in a research note on Wednesday, April 29th. Truist Financial reissued a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Citizens Jmp decreased their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $102.00.

Insider Buying and Selling

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently added to or reduced their stakes in the business. Dodge & Cox increased its position in Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock valued at $2,113,736,000 after acquiring an additional 290,676 shares during the period. State Street Corp grew its stake in shares of Zimmer Biomet by 2.3% in the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares during the last quarter. Invesco Ltd. grew its stake in shares of Zimmer Biomet by 10.6% in the fourth quarter. Invesco Ltd. now owns 3,361,075 shares of the medical equipment provider’s stock worth $302,228,000 after purchasing an additional 322,689 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Zimmer Biomet by 28.6% in the fourth quarter. Victory Capital Management Inc. now owns 2,475,768 shares of the medical equipment provider’s stock valued at $223,529,000 after purchasing an additional 551,005 shares during the period. Finally, Morgan Stanley raised its position in Zimmer Biomet by 8.6% during the 4th quarter. Morgan Stanley now owns 1,838,096 shares of the medical equipment provider’s stock worth $165,282,000 after purchasing an additional 144,789 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.